RUVBL1 promotes enzalutamide resistance of prostate tumors through the PLXNA1-CRAF-MAPK pathway. Sun F, Wang X, Hu J, Liu J, et al. Oncogene 2022;41:3239-3250.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sun F, Wang X, Hu J, Liu J, et al. RUVBL1 promotes enzalutamide resistance of prostate tumors through the PLXNA1-CRAF-MAPK pathway. Oncogene 2022;41:3239-3250.
PMID: 35508542